<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEUTROSPEC- technetium (99m tc) fanolesomabÂ 
			Â </strong><br>Mallinckrodt Inc.<br></p></div>
<h1>NEUTROSPEC<span class="Sup">TM</span><br>Kit for the Preparation of Technetium (99m Tc) fanolesomab</h1>
<div class="Contents">
<div class="Section">
<a name="dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-2"></a><p></p>
<p class="First">Diagnostic Radiopharmaceutical <br>For intravenous use only <br>Rx ONLY <br>CONTAINS SODIUM HYDROSULFITE</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NeutroSpec<span class="Sup">TM</span> [Kit for the Preparation of Technetium (99m Tc) fanolesomab] is a radiodiagnostic agent consisting of a murine IgM monoclonal antibody, formulated to be labeled with technetium Tc 99m.  Each NeutroSpec<span class="Sup">TM</span> kit contains all the excipients needed to reconstitute and to radiolabel this imaging agent with sodium pertechnetate Tc 99m Injection, USP.  The murine monoclonal antibody fanolesomab is produced in suspension culture of hybridoma cells.  NeutroSpec<span class="Sup">TM</span> [Technetium (99m Tc) fanolesomab] is an <span class="Italics">in vivo</span> diagnostic radiopharmaceutical that can be visualized by nuclear medicine instrumentation.</p>
<p>Each NeutroSpec<span class="Sup">TM</span> kit contains a single use vial of fanolesomab as a sterile, non-pyrogenic, lyophilized mixture of 0.25 mg fanolesomab; 12.5 mg maltose monohydrate; 0.522 mg sodium potassium tartrate tetrahydrate, USP; 0.221 mg succinic acid; 54 mcg stannous tartrate (minimum stannous 7 mcg; maximum total stannous and stannic tin 24 mcg); 28 mcg glycine, USP; and 9.3 mcg disodium edetate dihydrate, USP.  The lyophilized powder contains no preservatives and has no US standard of potency.</p>
<p>When sterile, pyrogen-free sodium pertechnetate Tc 99m Injection, USP in isotonic saline (no preservatives) is added to the single use fanolesomab vial, a Tc 99m complex of fanolesomab is formed with an approximate pH of 6.2.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-3.1"></a><p></p>
<h2>Physical Characteristics of Technetium Tc 99m</h2>
<p class="First">Technetium 99m decays by isomeric transition with a physical half-life of 6.02 hours. The photon that is useful for imaging studies is listed in <span class="Bold"><a href="#t1">Table 1</a></span>.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1.  Principal radiation emission data for technetium Tc 99m</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">Radiation</td>
<td class="Botrule Toprule" align="center" valign="top">Mean Percent per Disintegration</td>
<td class="Botrule Toprule" align="center" valign="top">Mean Energy (keV)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Gamma-2</td>
<td class="Botrule" align="center" valign="top">89.07</td>
<td class="Botrule" align="center" valign="top">140.5</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-3.2"></a><p></p>
<h2>External Radiation</h2>
<p class="First">The specific gamma-ray constant for technetium Tc 99m is 5.4 Î¼CÂ·kg<span class="Sup">-1</span>Â·MBq<span class="Sup">-1</span>Â·h<span class="Sup">-1</span> (0.78Â R/mCiÂ·h) at 1 cm.  The first half-value thickness of lead for Tc 99m is 0.017 cm.  A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of lead is shown in <span class="Bold"><a href="#t2">Table 2</a></span>.  For example, the use of a 0.25 cm thickness of lead will decrease the external <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> by a factor of 1,000.</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2.  Radiation attenuation by lead shielding</span></caption>
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Lead Shield Thickness (cm)</td>
<td class="Botrule Toprule" align="center" valign="middle">Coefficient of Attenuation</td>
</tr>
<tr>
<td align="center" valign="middle">0.017</td>
<td align="center" valign="middle">0.5</td>
</tr>
<tr>
<td align="center" valign="middle">0.08</td>
<td align="center" valign="middle">0.1</td>
</tr>
<tr>
<td align="center" valign="middle">0.16</td>
<td align="center" valign="middle">0.01</td>
</tr>
<tr>
<td align="center" valign="middle">0.25</td>
<td align="center" valign="middle">0.001</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">0.33</td>
<td class="Botrule" align="center" valign="middle">0.0001</td>
</tr>
</tbody>
</table>
<p>To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in <span class="Bold"><a href="#t3">Table 3</a></span>.</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3.  Physical decay chartâ€”technetium Tc 99m half-life 6.02 hours</span></caption>
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">*</span>Calibration Time (time of preparation)</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Hours</td>
<td class="Botrule Toprule" align="center" valign="middle">Fraction Remaining</td>
<td class="Botrule Toprule" align="center" valign="middle">Hours</td>
<td class="Botrule Toprule" align="center" valign="middle">Fraction Remaining</td>
</tr>
<tr>
<td align="center" valign="middle">0<span class="Sup">*</span>
</td>
<td align="center" valign="middle">1.00</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">0.45</td>
</tr>
<tr>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">0.89</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">0.40</td>
</tr>
<tr>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">0.79</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">0.36</td>
</tr>
<tr>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">0.71</td>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">0.32</td>
</tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">0.63</td>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">0.28</td>
</tr>
<tr>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">0.56</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">0.25</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">6</td>
<td class="Botrule" align="center" valign="middle">0.50</td>
<td class="Botrule" align="center" valign="middle">18</td>
<td class="Botrule" align="center" valign="middle">0.13</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Fanolesomab is directed against the carbohydrate moiety 3-fucosyl-<span class="Italics">N</span>-acetyllactosamine that defines the cluster of differentiation 15 (CD15) antigen.  NeutroSpec<span class="Sup">TM</span> [Technetium (99m Tc) fanolesomab] radiolabels human white blood cells and myeloid precursors.  The CD15 antigen is expressed on the surface of polymorphonuclear <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> (PMNs), eosinophils and monocytes.  Monocytes and eosinophils constitute approximately 5% of circulating leukocytes; therefore, most of the circulating blood cellular activity resides on PMNs.  In blood cell fractions isolated from healthy volunteers who had received NeutroSpec<span class="Sup">TM</span>, radioactivity was associated with PMNs (25%) or plasma (72%) when measured one hour after injection.  The binding of fanolesomab to its antigenic sites on human PMNs has an apparent <span class="Italics">K</span><span class="Sub">d</span> = 1.6 Ã— 10<span class="Sup">-11</span> M.</p>
<p>Cross-reactivity studies indicate the presence of CD15 antigenic sites on many human tissues.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">In a study of 10 healthy volunteers, following intravenous injection of NeutroSpec<span class="Sup">TM</span>, blood concentrations of radioactivity decreased rapidly with an initial half-life of 0.3 hours and a second phase half-life of approximately eight hours.  Whole-body scintigraphy at two hours post-injection indicated that the liver had the highest radioactivity uptake and retention (50% of the injected dose), followed by the kidney, spleen and red marrow.  Over the 26â€“33 hours after injection, 38% of the injected dose of radioactivity was recovered in urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">A multicenter, single-arm study evaluated 200 patients (5 to 86 years of age) with equivocal signs and symptoms of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> defined as absence of one or more of the following:  periumbilical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> migrating to right lower quadrant (RLQ), gradual onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, increasing intensity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> over time, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain aggravated</span> by movement and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, McBurney's point <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, referred <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> to RLQ with palpation in other quadrants, abdominal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscular spasm</span> with RLQ <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, temperature &gt; 101<span class="Sup">0</span> F, white blood cell count &gt; 10,500/mm<span class="Sup">3</span>.  Readers blinded to clinical information (except for age, gender and body habitus) assessed the diagnosis of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> by NeutroSpec<span class="Sup">TM</span>  imaging.  The diagnosis by the blinded readers was compared with a final clinical diagnosis based upon a surgical pathology report (in cases that proceeded to appendectomy) or upon two weeks of follow-up (in cases without <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>).  The study investigators had access to other diagnostic modalities (e.g., CT scan and ultrasound) and were instructed not to rely on NeutroSpec<span class="Sup">TM</span> imaging for their diagnosis of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span>.  <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">Appendicitis</span> prevalence in this study was 30%.  The image evaluation was limited to the assessment of the planar images performed in specified projections at defined time points and single photon emission tomography was not used to assess performance in this study.</p>
<p>The performance rates for the diagnosis of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> by the blinded readers and by the clinical investigators are shown in <span class="Bold"><a href="#t4">Table 4.</a></span></p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4.  Diagnostic performance of NeutroSpec<span class="Sup">TM</span></span></caption>
<col align="left" width="34.467%">
<col align="left" width="32.967%">
<col align="left" width="32.567%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Performance Rates<br>(n=200)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Evaluation</td>
<td class="Botrule Rrule" align="center" valign="top">Blinded Readers<br><br>percentages (95%CI)</td>
<td class="Botrule Rrule" align="center" valign="top">Study Investigators<br><br>percentages(95%CI)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sensitivity</td>
<td class="Botrule Rrule" align="center" valign="top">75 (62, 85)</td>
<td class="Botrule Rrule" align="center" valign="top">91 (80, 97)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Specificity</td>
<td class="Botrule Rrule" align="center" valign="top">93 (87, 97)</td>
<td class="Botrule Rrule" align="center" valign="top">86 (79, 91)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Accuracy</td>
<td class="Botrule Rrule" align="center" valign="top">87 (82, 92)</td>
<td class="Botrule Rrule" align="center" valign="top">87 (81, 91)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Positive Predictive Value</td>
<td class="Botrule Rrule" align="center" valign="top">82 (69, 91)</td>
<td class="Botrule Rrule" align="center" valign="top">74 (62, 84)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Negative Predictive Value</td>
<td class="Botrule Rrule" align="center" valign="top">90 (84, 94)</td>
<td class="Botrule Rrule" align="center" valign="top">96 (90, 99)</td>
</tr>
</tbody>
</table>
<p>In a supportive single-arm, two-center study of the detection of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> in 56 patients of whom 50% had a final diagnosis of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span>, the diagnostic performance of NeutroSpec<span class="Sup">TM</span> was similar to the performance observed in the larger study.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>Other intra-abdominal conditions</h2>
<p class="First">Among 30 study patients with other types of intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infection</span> (surgical and non-surgical), 13 scintigrams were read as positive for <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s10"></a><a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">NeutroSpec<span class="Sup">TM</span> [Technetium (99m Tc) fanolesomab] is indicated for scintigraphic imaging of patients with equivocal signs and symptoms of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> who are five years of age or older.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">NeutroSpec<span class="Sup">TM</span> should not be administered to patients who are hypersensitive to any murine proteins or other component of the product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s12"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, can occur in patients who receive murine antibodies such as fanolesomab.</p>
<p>Cenolate<span class="Sup">TM</span> Ascorbic Acid, USP injection (diluent) contains sodium hydrosulfite, a sulfite that may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.  Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> were not observed in the 523 patients who received NeutroSpec<span class="Sup">TM</span> in the clinical studies.  Emergency resuscitation personnel and equipment for the treatment of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be immediately available during administration of this agent.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s14"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-9.1"></a><p></p>
<h2>Repeat Administration</h2>
<p class="First">NeutroSpec<span class="Sup">TM</span> has not been studied in repeat administration to patients.  Murine monoclonal antibodies are frequently immunogenic.  The development of human anti-mouse antibodies (HAMA) can alter the pharmacokinetics, biodistribution, safety, and imaging performance properties of the administered agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-9.2"></a><p></p>
<h2>Use in Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">The biodistribution and the imaging performance of NeutroSpec<span class="Sup">TM</span> in neutropenic patients have not been studied.  NeutroSpec<span class="Sup">TM</span> induces transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and a downward shift in white blood cell counts.  (See <span class="Bold"><a href="#s26">ADVERSE REACTIONS Laboratory Values</a>)</span>.  The safety and effectiveness of NeutroSpec<span class="Sup">TM</span> in patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-9.3"></a><p></p>
<h2>General Use and Handling</h2>
<p class="First">NeutroSpec<span class="Sup">TM</span> [Technetium (99m Tc) fanolesomab], like other radioactive medical products, must be handled with care and appropriate safety measures should be used to minimize <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> to clinical personnel.  Care should also be taken to minimize <span class="product-label-link" type="condition" conceptid="438630" conceptname="Exposure to radiation">radiation exposure</span> to the patient consistent with proper patient management.</p>
<p>Radiopharmaceuticals should be used by or under the control of personnel who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s18"></a><a name="section-9.4"></a><p></p>
<h2>Information for patients</h2>
<p class="First">Murine monoclonal antibodies such as fanolesomab are foreign proteins and their administration can induce <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.  Patients should be informed that the use of this product could affect their future use of other murine based products, and should be advised to discuss prior use of murine antibody based products with their health care provider.</p>
<p>To minimize the radiation-absorbed dose to the bladder, adequate hydration should be encouraged to permit frequent voiding during the first few hours after injection.  To help protect themselves and others in their environment, patients should take the following precautions for 12 hours after injection.  Whenever possible, a toilet should be used, rather than a urinal and the toilet should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> several times after each use.  Spilled urine should be cleaned up completely.  After each voiding or fecal elimination, patients should thoroughly wash their hands.  If blood, urine or feces soil clothing, the clothing should be washed separately.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s19"></a><a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies have not been conducted to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s20"></a><a name="section-9.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-9.6.1"></a><p></p>
<p class="First">Pregnancy Category C.  Animal reproductive studies have not been conducted with NeutroSpec<span class="Sup">TM</span>.  It is also not known whether NeutroSpec<span class="Sup">TM</span> can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  NeutroSpec<span class="Sup">TM</span> should not be used during pregnancy unless the potential benefit to the patient justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s22"></a><a name="section-9.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when NeutroSpec<span class="Sup">TM</span> is administered to a nursing woman.  Whenever possible, infant formula should be substituted for breast milk until the radioactivity has cleared from the body of the nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s23"></a><a name="section-9.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">In clinical studies of NeutroSpec<span class="Sup">TM</span>, 29 (5%) patients were 5â€“11 years old and 32 (6%) were 12â€“16 years old.  No overall differences in safety or effectiveness were observed between these patients and patients in other age brackets, however, this number of patients is too few to exclude differences.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s24"></a><a name="section-9.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In clinical studies of NeutroSpec<span class="Sup">TM</span>, 64 (12%) patients were 65 years or older.  No overall differences in safety or effectiveness were observed between these patients and younger patients, but this number of patients is too few to exclude differences.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s25"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The data described below reflect exposure to NeutroSpec<span class="Sup">TM</span> in 523 patients and normal volunteers receiving a mean antibody dose of 121 mcg (33â€“250 mcg) and a mean radioactive dose of 15 mCi (1-33 mCi).  The median patient age was 35 years (5-91 years); 53% of patients were women and 61% of patients were Caucasians.</p>
<p>Two patients enrolled in studies of post surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> had serious adverse events associated with fatality (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and worsening of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>).  Underlying medical conditions may have also contributed to the fatality and the relationship of the fatality to NeutroSpecâ„¢ cannot be determined.</p>
<p>Overall, 49 adverse events occurred in 37 (7%) of the 523 patients exposed to NeutroSpec<span class="Sup">TM</span>.  Four of these events were classified as severe (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, worsening of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span> and decreased SaO<span class="Sub">2,</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>).  The most frequently reported adverse events were <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (n=10, 2%) and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (n=5, 1%).  Other less common adverse events (&lt; 1%) included <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site burning</span>/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Because clinical trials are conducted under widely varying controlled conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug, and may not reflect the rates observed in practice.  The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<div class="Section" data-sectionCode="34075-2">
<a name="s26"></a><a name="section-10.1"></a><p></p>
<h2>Laboratory Test Values</h2>
<p class="First">NeutroSpec<span class="Sup">TM</span> induced transient decreases in neutrophil counts in a study of 10 healthy volunteers.   Neutrophil counts began to decrease within 3 to 5 minutes post-injection and returned to pre-injection values within four hours.  Downward shifts in neutrophil counts have been observed in 18% of patients (28/151).  Three of 284 patients were observed to develop transient elevations of AST and ALT after NeutroSpec<span class="Sup">TM</span> administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-10.2"></a><p></p>
<h2>Immunogenicity</h2>
<p class="First">The incidence of antibody development in patients receiving NeutroSpec<span class="Sup">TM</span> has not been adequately determined because the assay was not directly quantitative and its ability to detect low titers could not be assured.  Human anti-mouse antibody (HAMA) response following a single NeutroSpec<span class="Sup">TM</span> administration was evaluated in a total of 54 patients 3-16 weeks post injection.  None of the patients had a positive HAMA response.  In 30 healthy volunteers who were exposed to two administrations of fanolesomab separated by two weeks, fanolesomab induced HAMA response in five volunteers.</p>
<p>Immunogenicity data are highly dependent on the sensitivity and specificity of the assay.  Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease.  For these reasons, comparison of the incidence of antibodies to NeutroSpec<span class="Sup">TM</span> with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s28"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no experience with overdosage in clinical trials.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s29"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-12.1"></a><p></p>
<h2>Adults</h2>
<p class="First">To prepare NeutroSpec<span class="Sup">TM</span> the reaction vial containing fanolesomab is reconstituted with sodium pertechnetate Tc 99m Injection, USP solution prior to use. (See <span class="Bold"><a href="#s34">INSTRUCTIONS FOR PREPARATION</a></span>).</p>
<p>Fanolesomab is not intended for direct administration to the patient without reconstitution and labeling with sodium pertechnetate Tc 99m Injection, USP.  NeutroSpec<span class="Sup">TM</span> [Technetium (99m Tc) fanolesomab] is intended for a single intravenous (IV) administration through an intravenous access that has been demonstrated to be patent, e.g., butterfly, running IV line, or equivalent injection system to assure that no dose infiltration occurs.  Following administration, flush the injection line with an appropriate volume of saline to assure administration of the total dose.</p>
<p>For imaging, 75 to 125 mcg of fanolesomab is labeled with 10 to 20 mCi (370 to 740 MBq) and administered as a single dose of NeutroSpec<span class="Sup">TM</span>.</p>
<p>Planar imaging should be performed using a large field of view camera fitted with a low-energy, parallel-hole, high-resolution collimator.  The camera should be positioned so that the lower edge of the liver is at the upper end of the field of view at the midline of the patient.</p>
<p>Dynamic image acquisition over the lower abdomen should begin at the time of injection and consist of 10 sequential four-minute images.  Following dynamic image acquisition, the patient should ambulate for approximately 10 to 15 minutes and void.  Static planar images should then be collected, including supine anterior, posterior, 10â€“25 degree RAO and LAO views of the lower abdomen, followed by a standing anterior image of the lower abdomen.  After the camera has been positioned (as described above), it is recommended that a total of one million counts be collected for the anterior supine image.  All remaining images should be collected for the same duration of time required for the anterior supine image.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-12.2"></a><p></p>
<h2>Children (Five years and older)</h2>
<p class="First">NeutroSpec<span class="Sup">TM</span> is administered in a single dose of 0.21 mCi/kg to a maximum of 20 mCi.  Recommended imaging times and procedures are the same as for adults.</p>
<p>Dose adjustment has not been established in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, in geriatric patients or in pediatric patients under five years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-12.3"></a><p></p>
<h2>Image Interpretation</h2>
<p class="First">The biodistribution of the NeutroSpec<span class="Sup">TM</span> radiopharmaceutical is imaged in the blood pool, reticuloendothelial system (liver, spleen, bone marrow), and urinary excretion organs (kidneys and urinary tract).  Imaging of the uterus has been noted, consistent with blood pool activity of NeutroSpec<span class="Sup">TM</span>.</p>
<p>In the 200-patient clinical trial (see <a href="#s8">CLINICAL STUDIES</a>), based on the average of the three blinded reader interpretations, 75% of the 59 true positive cases of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> were identified (range 66-81%).</p>
<p>Among those with a blinded diagnosis of <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span>, 76% displayed uptake of radiotracer activity in the appendix within 30 minutes following injection and 98% did so by 60 minutes following injection.</p>
<p>In the trial the acquisition of image collection was performed for a 90 minute period.  The image finding of a persistent or intensifying uptake in the right lower quadrant (appendix zone) that is seen before the completion of the entire imaging sequence may be considered a positive study, and imaging may be terminated at this time.  In the case of a negative image finding at 30 and 60 minutes, collection to 90 minutes is recommended prior to termination of the study.</p>
<p>A diagnostic abnormality is characterized by the presence of an irregular, asymmetric uptake of radiotracer localized in the right lower quadrant of the abdomen.  The abnormal localization of radiotracer remains constant or increases in intensity in follow up imaging.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-13"></a><p></p>
<h1>RADIATION DOSIMETRY</h1>
<p class="First">Based on human data, the absorbed radiation dose to an average human adult (70 kg) from an intravenous injection of NeutroSpec<span class="Sup">TM</span> is listed in <span class="Bold"><a href="#t5">Table 5</a></span>.  The values were calculated using the Standard Medical Internal Radiation Dosimetry (MIRD) method.  The values are listed as rad/mCi and mGy/MBq and assume urinary bladder emptying at 4.8Â hours.  Radiation absorbed dose estimates for children are given in <span class="Bold"><a href="#t6">Table 6.</a></span></p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5.  Absorbed radiation dose in adults (NeutroSpec<span class="Sup">TM</span>)</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No. 1 rev., Soc. Nucl. Med., 1976).  Effective dose equivalent was calculated in accordance with ICRP 53 (Ann. ICRP 18, 1-4, 1988) and gave a value of 0.018 mSv/MBq (0.068 rem/mCi).</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">Target Organ</td>
<td class="Botrule Toprule" align="center" valign="middle">rad/mCi</td>
<td class="Botrule Toprule" align="center" valign="middle">mGy/MBq</td>
</tr>
<tr>
<td align="left" valign="middle">Spleen</td>
<td align="center" valign="middle">0.23</td>
<td align="center" valign="middle">0.062</td>
</tr>
<tr>
<td align="left" valign="middle">Kidneys</td>
<td align="center" valign="middle">0.19</td>
<td align="center" valign="middle">0.051</td>
</tr>
<tr>
<td align="left" valign="middle">Liver</td>
<td align="center" valign="middle">0.18</td>
<td align="center" valign="middle">0.048</td>
</tr>
<tr>
<td align="left" valign="middle">Urinary Bladder Wall</td>
<td align="center" valign="middle">0.12</td>
<td align="center" valign="middle">0.032</td>
</tr>
<tr>
<td align="left" valign="middle">Heart</td>
<td align="center" valign="middle">0.061</td>
<td align="center" valign="middle">0.017</td>
</tr>
<tr>
<td align="left" valign="middle">Gallbladder</td>
<td align="center" valign="middle">0.056</td>
<td align="center" valign="middle">0.015</td>
</tr>
<tr>
<td align="left" valign="middle">Upper Large Intestine Wall</td>
<td align="center" valign="middle">0.051</td>
<td align="center" valign="middle">0.014</td>
</tr>
<tr>
<td align="left" valign="middle">Adrenal Glands</td>
<td align="center" valign="middle">0.044</td>
<td align="center" valign="middle">0.012</td>
</tr>
<tr>
<td align="left" valign="middle">Lungs</td>
<td align="center" valign="middle">0.043</td>
<td align="center" valign="middle">0.012</td>
</tr>
<tr>
<td align="left" valign="middle">Thyroid Gland</td>
<td align="center" valign="middle">0.042</td>
<td align="center" valign="middle">0.011</td>
</tr>
<tr>
<td align="left" valign="middle">Red Marrow</td>
<td align="center" valign="middle">0.038</td>
<td align="center" valign="middle">0.010</td>
</tr>
<tr>
<td align="left" valign="middle">Lower Large Intestine Wall</td>
<td align="center" valign="middle">0.034</td>
<td align="center" valign="middle">0.0091</td>
</tr>
<tr>
<td align="left" valign="middle">Bone Surface</td>
<td align="center" valign="middle">0.031</td>
<td align="center" valign="middle">0.0083</td>
</tr>
<tr>
<td align="left" valign="middle">Brain</td>
<td align="center" valign="middle">0.0052</td>
<td align="center" valign="middle">0.0014</td>
</tr>
<tr>
<td align="left" valign="middle">Testes / Ovaries</td>
<td align="center" valign="middle">0.0039 / 0.019</td>
<td align="center" valign="middle">0.0010 / 0.0052</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Total Body</td>
<td class="Botrule" align="center" valign="middle">0.019</td>
<td class="Botrule" align="center" valign="middle">0.0050</td>
</tr>
</tbody>
</table>
<a name="t6"></a><table width="100%">
<caption><span>Table 6.  Estimated absorbed radiation dose for a five-year old child</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">Dose calculations were performed using the standard MIRD method based upon biodistribution studies conducted in adults.  Effective dose equivalent was calculated in accordance with ICRP 53 and gave a value of 0.047 mSv/MBq (0.17Â rem/mCi).</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="middle">Target Organ</td>
<td class="Botrule Toprule" align="center" valign="middle">rad/mCi</td>
<td class="Botrule Toprule" align="center" valign="middle">mGy/MBq</td>
</tr>
<tr>
<td align="left" valign="middle">Spleen</td>
<td align="center" valign="middle">0.70</td>
<td align="center" valign="middle">0.19</td>
</tr>
<tr>
<td align="left" valign="middle">Kidneys</td>
<td align="center" valign="middle">0.43</td>
<td align="center" valign="middle">0.11</td>
</tr>
<tr>
<td align="left" valign="middle">Liver</td>
<td align="center" valign="middle">0.41</td>
<td align="center" valign="middle">0.11</td>
</tr>
<tr>
<td align="left" valign="middle">Urinary Bladder Wall</td>
<td align="center" valign="middle">0.27</td>
<td align="center" valign="middle">0.072</td>
</tr>
<tr>
<td align="left" valign="middle">Upper Large Intestine Wall</td>
<td align="center" valign="middle">0.21</td>
<td align="center" valign="middle">0.056</td>
</tr>
<tr>
<td align="left" valign="middle">Thyroid Gland</td>
<td align="center" valign="middle">0.19</td>
<td align="center" valign="middle">0.052</td>
</tr>
<tr>
<td align="left" valign="middle">Lower Large Intestine Wall</td>
<td align="center" valign="middle">0.16</td>
<td align="center" valign="middle">0.042</td>
</tr>
<tr>
<td align="left" valign="middle">Heart</td>
<td align="center" valign="middle">0.15</td>
<td align="center" valign="middle">0.041</td>
</tr>
<tr>
<td align="left" valign="middle">Gallbladder</td>
<td align="center" valign="middle">0.13</td>
<td align="center" valign="middle">0.036</td>
</tr>
<tr>
<td align="left" valign="middle">Red Marrow</td>
<td align="center" valign="middle">0.11</td>
<td align="center" valign="middle">0.030</td>
</tr>
<tr>
<td align="left" valign="middle">Lungs</td>
<td align="center" valign="middle">0.11</td>
<td align="center" valign="middle">0.028</td>
</tr>
<tr>
<td align="left" valign="middle">Adrenal Glands</td>
<td align="center" valign="middle">0.095</td>
<td align="center" valign="middle">0.026</td>
</tr>
<tr>
<td align="left" valign="middle">Bone Surface</td>
<td align="center" valign="middle">0.085</td>
<td align="center" valign="middle">0.023</td>
</tr>
<tr>
<td align="left" valign="middle">Testes / Ovaries</td>
<td align="center" valign="middle">0.019 / 0.059</td>
<td align="center" valign="middle">0.0052 / 0.016</td>
</tr>
<tr>
<td align="left" valign="middle">Brain</td>
<td align="center" valign="middle">0.0075</td>
<td align="center" valign="middle">0.0020</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Total Body</td>
<td class="Botrule" align="center" valign="middle">0.049</td>
<td class="Botrule" align="center" valign="middle">0.013</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-14"></a><p></p>
<h1>INSTRUCTIONS FOR THE PREPARATION OF NEUTROSPEC<span class="Sup">TM</span>
</h1>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-15"></a><p></p>
<h1>USE ASEPTIC TECHNIQUE THROUGHOUT</h1>
<p class="First">The user should wear waterproof gloves during the entire procedure and while withdrawing the patient dose from the NeutroSpec<span class="Sup">TM</span> vial.</p>
<p>Transfer Sodium Pertechnetate Tc 99m Injection, USP with an adequately shielded, sterile syringe.</p>
<p>Adequate shielding should be maintained at all times until the preparation is administered to the patient, disposed of in an approved manner, or allowed to decay to background levels.  A shielded, sterile syringe should be used to withdraw and inject the labeled preparation.</p>
<p>Before reconstituting a vial, it should be inspected for cracks and any indication that the integrity of the vacuum seal has been lost.  The material should not be used if integrity of the vacuum seal has been lost.  After reconstitution, examine the vial contents for particulates and discoloration prior to injection.  The material should not be used if particulates or discoloration are observed.</p>
<p>The dose should be injected via an indwelling catheter, butterfly, or equivalent injection system to assure that no dose infiltration occurs.  Following administration, flush the injection line with an appropriate volume of saline to assure administration of the total dose.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-15.1"></a><p></p>
<h2>Labeling and Preparation of NeutroSpec<span class="Sup">TM</span>
</h2>
<ol class="Arabic">
<li>Required Materials, Not Supplied within the NeutroSpec<span class="Sup">TM</span> kit:<ol class="LittleAlpha">
<li><span class="Bold"> Sodium Pertechnetate Tc-99m, USP, oxidant-free</span></li>
<li><span class="Bold"> ITLC-SG Strips, Heat Treated</span></li>
<li><span class="Bold"> Methyl Ethyl Ketone (MEK)</span></li>
<li><span class="Bold"> Developing Chambers - 50 mL disposable tubes</span></li>
<li><span class="Bold"> Pipettors and tips</span></li>
<li><span class="Bold"> Forceps</span></li>
<li><span class="Bold"> Gamma Counter</span></li>
<li><span class="Bold"> Dose Calibrator</span></li>
<li><span class="Bold"> Sodium Chloride for Injection, USP</span></li>
<li><span class="Bold"> Alcohol (or Germicidal)</span></li>
<li><span class="Bold"> Lead Shield</span></li>
<li><span class="Bold"> 1 mL Sterile Syringes</span></li>
<li><span class="Bold"> Water Bath stabilized at 37Â±1Â° C</span></li>
</ol>
</li>
<li>Remove a fanolesomab reaction vial from refrigerated storage (2 to 8Â° C) and allow it to come to room temperature (usually 5 to 10 minutes).  NOTE:  Keep Cenolate ampule refrigerated and protected from light until needed (Step 5).</li>
<li>Swab the rubber stopper of the fanolesomab reaction vial with an appropriate antiseptic and allow the stopper to dry.</li>
<li>Aseptically add 20 to 40 mCi (740 to 1480 MBq) Sodium Pertechnetate Tc 99m Injection, USP in 0.20 to 0.35 mL generator eluate.  Gently swirl (<span class="Bold">Do not shake</span>) the vial until the lyophilized product is completely dissolved, ensuring the vial is not inverted.<br><span class="Bold">Cautionary Notes:</span><ul class="Disc">
<li><span class="Bold">Use only eluate from a technetium Tc 99m generator that was previously eluted within the last 24 hours.</span></li>
<li><span class="Bold">Technetium 99m eluate which is more than 8 hours old from the time of elution should NOT be used.</span></li>
<li><span class="Bold">The amount of Sodium Pertechnetate Tc 99m Injection, USP used to reconstitute the reaction vial should be determined based on the desired radioactive dose and the estimated time of use.</span></li>
<li><span class="Bold">If Sodium Pertechnetate Tc 99m Injection, USP must be diluted prior to kit reconstitution, only sterile sodium chloride for injection, USP, (without preservatives) should be used.</span></li>
</ul>
</li>
<li>Incubate at 37Âº C for 30 minutes.  (Shorter incubation times may result in inadequate labeling.)</li>
<li>Aseptically add sufficient Cenolate<span class="Sup">TM</span> [Ascorbic Acid Injection, USP (500 mg/mL)] to make the final preparation volume up to 1 mL.<br><span class="Bold">Note: Further dilution is not recommended.</span>
</li>
<li>Assay the product in a suitable calibrator and record the time, date of preparation and the activity of NeutroSpec<span class="Sup">TM</span> onto the string tag label and attach to lead dispensing shield (â€œpigâ€?).</li>
<li>Each patient should receive a dose of 10-20 mCi of NeutroSpec<span class="Sup">TM</span> (the final reconstituted product).</li>
<li>Discard vials, needles and syringes in accordance with local, state, and federal regulations governing radioactive and biohazardous waste.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-15.2"></a><p></p>
<h2>Recommended Method for Radiochemical Purity Testing</h2>
<ol class="Arabic">
<li>After addition of Cenolate<span class="Sup">TM</span> (Ascorbic Acid Injection, USP) aseptically withdraw approximately 10 Î¼L of the final reconstituted product for Quality Control (QC) testing.  Care should be taken not to introduce air into the vial.  Use of a shielded 0.5 - 1.0 cc syringe with a 25 or 27 gauge needle is recommended.</li>
<li>Apply 1 - 5 Î¼L (a drop that has not completely formed on the tip of a 25 - 27 gauge needle) of NeutroSpec<span class="Sup">TM</span> 2 cm (origin) from the bottom of an ITLC-SG 1.5 x 10 cm strip and allow the solution to absorb into the strip (approximately 5 seconds).</li>
<li>Immediately place the strip, origin side down, in a development chamber containing 4 mL methyl ethyl ketone (MEK).</li>
<li>Allow the strip to develop until the solvent front is within 0.5 cm of the top of the strip (3 - 5 minutes).</li>
<li>Remove the strip using forceps and allow to dry.</li>
<li>Cut the strip at the 4 cm mark, place each piece in a separate counting tube and measure the radioactivity associated with each piece.</li>
<li>Calculate the % Free Technetium Tc 99m Pertechnetate as follows:</li>
</ol>
<table width="100%">
<col align="left" width="33.000%">
<col align="left" width="33.000%">
<col align="left" width="34.000%">
<tbody class="Headless">
<tr class="First">
<td align="right" valign="top">% Free PertechnetateÂ Â Â Â Â  =</td>
<td align="center" valign="top">
<span class="Underline">Radioactivity in Solvent Front Piece</span>    x    100%</td>
<td align="right" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="center" valign="top">Total Radioactivity in Strip</td>
<td align="right" valign="top"></td>
</tr>
</tbody>
</table>
<p class="First"><span class="Bold">Note: The product should only be used if the percentage of Free Technetium Tc 99m Pertechnetate is â‰¤ 10%.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s38"></a><a name="section-16"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NeutroSpec<span class="Sup">TM</span> Kit for the Preparation of Technetium (99m Tc) fanolesomab</p>
<p>The NeutroSpec<span class="Sup">TM</span> kit contains five individual kits each containing:</p>
<table width="100%">
<col align="left" width="27.900%">
<col align="left" width="72.100%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">One</td>
<td align="left" valign="top">3 mL single use vial of fanolesomab as a sterile, non-pyrogenic, lyophilized mixture of 0.25 mg fanolesomab; 12.5 mg maltose monohydrate; 0.522 mg sodium potassium tartrate tetrahydrate, USP; 0.221 mg succinic acid; 54 mcg stannous tartrate (minimum stannous 7 mcg; maximum total stannous and stannic tin 24 mcg); 28 mcg glycine, USP; and 9.3 mcg disodium edetate dihydrate, USP.  The lyophilized powder contains no preservatives and has no US standard of potency.</td>
</tr>
<tr>
<td align="left" valign="top">One</td>
<td align="left" valign="top">2 mL ampule Cenolate<span class="Sup">TM</span> [Ascorbic Acid Injection, USP<br>(500 mg/mL)]</td>
</tr>
<tr>
<td align="left" valign="top">One</td>
<td align="left" valign="top">NeutroSpec<span class="Sup">TM</span> Package Insert</td>
</tr>
<tr class="Last">
<td align="left" valign="top">One</td>
<td align="left" valign="top">String tag label for NeutroSpec<span class="Sup">TM</span> vials (reconstituted product)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s39"></a><a name="section-17"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Refrigerate the lyophilized NeutroSpec<span class="Sup">TM</span> kits at 2 to 8Â° C (36 to 46Â° F).  After labeling with Sodium Pertechnetate TcÂ 99m Injection, USP and addition of Cenolate<span class="Sup">TM</span> (Ascorbic Acid injection, USP) the vial should be kept at room temperature, 15 to 25Â° C (46 to 77Â° F) and used within <span class="Bold Underline">six</span> hours.  Use appropriate radiation shielding.</p>
<p>This reagent kit is approved for distribution to persons licensed by the U.S. Nuclear Regulatory Commission to use byproduct material identified in 10 CFR 35.200 or under an equivalent license issued by an Agreement State.</p>
<p>NeutroSpec<span class="Sup">TM</span> is manufactured for Palatin Technologies, Inc., Cranbury, NJ 08512 by Ben Venue Laboratories, Inc., Bedford, OH 44146 <br>U.S. Patent X,XXX,XXX<br>US license number 1588</p>
<p>Cenolate<span class="Sup">TM</span> (Ascorbic Acid Injection, USP) is manufactured for Palatin Technologies, Inc. by Hospira, Chicago, IL 60064</p>
<p><span class="Bold">Distributed by:<br></span>Mallinckrodt Inc.<br>St. Louis, MO 63134</p>
<p>Rx only</p>
<p>Printed in USA<br>NeutroSpec<span class="Sup">TM</span> is a registered trademark of Palatin Technologies, Inc.<br>Cenolate is a registered trademark of Hospira.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEUTROSPECÂ 		
					</strong><br><span class="contentTableReg">technetium (99m tc) fanolesomab kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:1500-9623</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:1500-9623-01</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1  </td>
<td class="formItem">1Â </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1  </td>
<td class="formItem">2Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>NEUTROSPECÂ 		
					</strong><br><span class="contentTableReg">neutrospec injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Fanolesomab</strong> (Fanolesomab) </td>
<td class="formItem"></td>
<td class="formItem">0.25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>maltose monohydrate</strong></td>
<td class="formItem">12.5Â mg Â inÂ 1Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium potassium tartrate tetrahydrate</strong></td>
<td class="formItem">0.522Â mg Â inÂ 1Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>succinic acid</strong></td>
<td class="formItem">0.221Â mg Â inÂ 1Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stannous tartrate</strong></td>
<td class="formItem">54Â ug Â inÂ 1Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycine</strong></td>
<td class="formItem">28Â ug Â inÂ 1Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>disodium edetate dihydrate</strong></td>
<td class="formItem">9.3Â ug Â inÂ 1Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>CENOLATEÂ 		
					</strong><br><span class="contentTableReg">sodium ascorbate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-3397</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sodium Ascorbate</strong> (Ascorbic acid) </td>
<td class="formItem"></td>
<td class="formItem">500Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydrosulfite</strong></td>
<td class="formItem">5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>aluminum</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-3397-52</td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mallinckrodt Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>B9CC9124-DF9E-C8CF-B50E-CCAC9A90C399</div>
<div>Set id: af67a2f3-65b7-4a6e-9a51-315a280f976b</div>
<div>Version: 1</div>
<div>Effective Time: 20071001</div>
</div>
</div>Â <div class="DistributorName">Mallinckrodt Inc.</div></p>
</body></html>
